DNMT1 and ovarian carcinoma: The II phase clinical trial on DNMT1 inhibitor decitabine combined with platinum-based chemotherapy was performed in the group of 29 patients with recurrent partially chemo-sensitive (relapse 6–12 months after first line chemotherapy) ovarian cancer.